About: Coping with hypoxemia: Could erythropoietin (EPO) be an adjuvant treatment of COVID-19?

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Coping with hypoxemia: Could erythropoietin (EPO) be an adjuvant treatment of COVID-19? Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Coping with hypoxemia: Could erythropoietin (EPO) be an adjuvant treatment of COVID-19?
Creator	Arias-Reyes, Christian Dutschmann, Mathias Poma-Machicao, Liliana Schneider-Gasser, Edith Soliz, Jorge Zubieta-Calleja, Gustavo Aliaga-Raduan, Fernanda Dhingra, Rishi Furuya, Werner Trevizan-Baú, Pedro
Source	Elsevier; Medline; PMC
abstract	A very recent epidemiological study provides preliminary evidence that living in habitats located at 2500 m above sea level and higher might protect from the development of severe respiratory symptoms following infection with the novel SARS-CoV-2 virus. This epidemiological finding raises the question of whether physiological mechanisms underlying the acclimatization to high altitude identifies therapeutic targets for the effective treatment of severe acute respiratory syndrome pivotal to the reduction of global mortality during the COVID-19 pandemic. This article compares the symptoms of acute mountain sickness (AMS) with those of SARS-CoV-2 infection and explores overlapping patho-physiological mechanisms of the respiratory system including impaired oxygen transport, pulmonary gas exchange and brainstem circuits controlling respiration. In this context, we also discuss the potential impact of SARS-CoV-2 infection on oxygen sensing in the carotid body. Finally, since erythropoietin (EPO) is an effective treatment for AMS, this article reviews the potential benefits of implementing FDA-approved erythropoietin-based (EPO) drug therapies to counteract a variety of acute respiratory and non-respiratory (e.g. excessive inflammation of vascular beds) symptoms of SARS-CoV-2 infection. High-altitude environments of 2500 m above sea level (masl) are characterized by barometric hypoxia. Chronic exposure to hypobaric hypoxia in such extreme and adverse environments evokes short- and long-term physiologic adaptations to maintain tissue oxygen levels at high altitude in animals and humans. Recent work suggests that high altitude dewellers, in particular in American countries and Tibet (Arias-Reyes et al., 2020; Ortiz-Prado et al., 2020), may present with lower infection rates and/or less severe symptoms of COVID-19 compared to lowlanders (Arias-Reyes et al., 2020; Lei et al., 2020; Ortiz-Prado et al., 2020). This epidemiologic finding raises the question of whether physiological mechanisms underlying the acclimatization to high altitude or in turn the development of acute mountain sickness (AMS), may provide potential avenues for understanding the severity of symptoms and treatment of SARS-CoV-2 infection. Here, we provide a survey of similarities of acute mountain sickness to COVID-19 and suggest that the physiologic response to high altitude, characterized by an increase in erythropoietin (EPO), may provide a framework to develop an adjuvant therapy in COVID-19. Indeed, a recently published case study from Iran supports EPO as an effective treatment of severe COVID-19 patho-physiology (Hadadi et al., 2020).
has issue date	2020-06-06(xsd:dateTime)
bibo:doi	10.1016/j.resp.2020.103476
bibo:pmid	32522574
has license	no-cc
sha1sum (hex)	72a62993cea1bea7085844a676df99c5cadcd1fb
schema:url	https://doi.org/10.1016/j.resp.2020.103476
resource representing a document's title	Coping with hypoxemia: Could erythropoietin (EPO) be an adjuvant treatment of COVID-19?
has PubMed Central identifier	PMC7275159
has PubMed identifier	32522574
schema:publication	Respir Physiol Neurobiol
resource representing a document's body	covid:72a62993cea1bea7085844a676df99c5cadcd1fb#body_text
is schema:about of	named entity 'mechanisms' named entity 'hypoxemia' named entity 'Erythropoietin' named entity 'DATA' named entity 'SARS-COV-2' covid:arg/72a62993cea1bea7085844a676df99c5cadcd1fb named entity 'therapeutic' named entity 'infection' named entity 'Coping' named entity 'SARS-CoV-2 virus' named entity 'adjuvants' named entity 'COVID' named entity 'prophylaxis' named entity 'AMS' named entity 'Epidemiological data' named entity 'COVID' named entity 'COVID' named entity 'SARS-CoV-2' named entity 'EPO' named entity 'hypoxemia' named entity 'venous thromboembolism' named entity 'hypoxemia' named entity 'infection' named entity 'EPO' named entity 'alveoli' named entity 'brainstem' named entity 'blood-brain barrier' named entity 'COVID-19' named entity 'acute mountain sickness' named entity 'anti-coagulant' named entity 'endothelial' named entity 'EPO' named entity 'vascular bed' named entity 'hypoxia' named entity 'inflammation' named entity 'acclimatization' named entity 'oxygen' named entity 'EPO' named entity 'inflammation' named entity 'respiratory frequency' named entity 'Hyperventilation' named entity 'muscle ache' named entity 'COVID-19' named entity 'COVID' named entity 'hypoxia' named entity 'infection' named entity 'oxygen' named entity 'cytokine storm' named entity 'EPO' named entity 'natriuresis' named entity 'erythrocytes' named entity 'hyperventilation' named entity 'patho' named entity 'hypovolemia' named entity 'high-altitude pulmonary edema' named entity 'intensive care' named entity 'COVID' named entity 'hypoxemia' named entity 'EPO' named entity 'SARS-CoV-2' named entity 'erythrocytes' named entity 'inflammation' named entity 'COVID-19' named entity 'hypoxic' named entity 'vasoconstriction' named entity 'hypoxia' named entity 'high-altitude hypoxia' named entity 'EPO' named entity 'loss of red blood cells' named entity 'acclimatization' named entity 'COVID-19' named entity 'autopsies'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software